If you’re into the world of aesthetics (and we’re pretty sure you are, considering you’re here), you’ve likely heard of Evolus—or at least its popular neurotoxin, Jeuveau, which received FDA approval in 2019 for the temporary treatment of moderate to severe glabellar lines. Now, the brand is back in the spotlight with the FDA approval of its Evolysse™ collection, a new line of injectable hyaluronic acid gels designed for dynamic areas of the face. Meet Evolysse™ Form and Evolysse™ Smooth, the latest innovations coming soon to the injectable world.
Evolus announced the news today via social media, giving its followers a first look at the highly anticipated new products. As explained in the caption of an Instagram post, “these injectable hyaluronic acid gels utilize cutting-edge Cold-X™ Technology, which uses near-freezing temperatures aimed at preserving the natural structure of hyaluronic acid (HA),” the post reads. Evolysse Form is designed to provide lift and support, while Evolysse Smooth, as its name suggests, helps soften and smooth lines. Both are said to be available in quarter two or spring of this year, per the Evolus website.
“This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty,” said David Moatazedi, President and Chief Executive Officer of Evolus. “Evolysse™ Form and Evolysse™ Smooth represent the first major technological breakthrough in HA dermal fillers in a decade, offering our customers and consumers a new standard in performance and innovation. The launch of these products is a catalyst in our growth as we are focused on achieving at least $700 million in net revenue and non-GAAP operating income margin of at least 20% by 2028.”
